MANAGEMENT OF ENDOCRINE DISEASE: Clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies

摘要: Pituitary tumours, the most frequent intracranial tumour, are historically considered benign. However, various pieces of clinical evidence and recent advances in pathological molecular analyses suggest need to consider these tumours as more than an endocrinological disease, despite low incidence metastasis. Recently, we proposed a new prognostic clinicopathological classification pituitary according tumour size (micro, macro giant), type (prolactin, GH, FSH/LH, ACTH TSH) grade (grade 1a, non-invasive; 1b, non-invasive proliferative; 2a, invasive; 2b, invasive proliferative 3, metastatic). In addition this classification, numerous markers have been identified, allowing better characterisation behaviour prognosis. Moreover, preclinical studies demonstrated that could be treated by some chemotherapeutic drugs or targeted therapies. Our improved should now allow identification prognosis help clinician propose personalised therapies selected patients presenting with high risk recurrence.